Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Book a discovery call with a Concierge MD provider to discuss whether bremelanotide is a fit and what a personalized treatment plan would look like for you
A narrative research review found early evidence that GLP-1 medications may improve some sperm measures or testosterone levels in men with obesity or metabolic hypogonadism (a condition that impacts hormone production)
Limited access moving forward If you rely on compounded semaglutide, your medication may soon be unavailable, requiring a shift to FDA-approved options
Mochi Health's $348$498/mo ($4,176$5,976/year)
(NYSE: PFE) is the world's second-largest pharmaceutical company by 2024 revenue at USD 63.6 billion, but its ranking at #7 in the peptide therapy context reflects the company's limited direct exposure to the GLP-1/GIP revolution that defines the market's highest-growth segment
The "direct-to-employer" access model allows employers to work directly with a vendor to provide GLP-1 medications to eligible employees, bypassing PBMs, allowing for more pricing transparency and control
US$ 21.86
US$ 21.49
US$ 21.65
US$ 24.23
.jpg)
US$ 24.62
